VINCREX Drug Patent Profile
✉ Email this page to a colleague
When do Vincrex patents expire, and when can generic versions of Vincrex launch?
Vincrex is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in VINCREX is vincristine sulfate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the vincristine sulfate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VINCREX?
- What are the global sales for VINCREX?
- What is Average Wholesale Price for VINCREX?
Summary for VINCREX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 45 |
| Clinical Trials: | 87 |
| Patent Applications: | 3,055 |
| DailyMed Link: | VINCREX at DailyMed |
Recent Clinical Trials for VINCREX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| City of Hope Medical Center | Phase 1 |
| Yazeed Sawalha | Phase 1 |
| Memorial Sloan Kettering Cancer Center | Early Phase 1 |
US Patents and Regulatory Information for VINCREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | VINCREX | vincristine sulfate | INJECTABLE;INJECTION | 070867-001 | Jul 12, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
